VIROLOGY DIAGNOSIS AND TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS-INFECTIONS

Respiratory syncytial virus infections occur frequently in children, often localized in the upper respiratory tract. Outcome is usually quite satisfactory, but in nearly one half of the infants lower tract involvement may cause severe respiratory insufficiency leading to hospitalization in about 1% of the cases. Its frequency has been estimated at 20 to 30% of the viral infections in hospitalized infants, 10 times the frequency of the other respiratory virus. Respiratory syncytial epidemias last about 4 to 5 months with a seasonal peak in december and january. The direct detection of respiratory syncytial antigens in nasal specimens by immunofluorescence or enzymatic immunoassay is the key to rapid diagnosis. They appear as performant and more convenient than specific IgM antibodies or nucleic acid detections, and than virus isolation on cell culture, which is justified to evaluate strain sensitivity to ribavirin. Immunofluorescence has also been used to identify the subgroups A and B from 1981 to 1993, and respiratory syncytial subgroup A seems to signify more severe disease. Symptomatic assistance may require hydratation, oxygenotherapy and respiratory physical therapy. Antibiotics should not be given as a routine treatment since bacterial superinfection is infrequent, but may be indicated in cases with associated signs of complications. Indications for bronchodilators and corticosteroids are still under debate. Significant results have been obtained with ribavirin and specific anti respiratory syncytial immunoglobulins but further evaluations are still required to precise their use in clinical practice.